Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, United States.
J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 15;941:100-8. doi: 10.1016/j.jchromb.2013.10.011. Epub 2013 Oct 16.
The development and validation of a LC-MS/MS method is often performed using pooled human plasma, which may fail to account for variations in interindividual matrices. Since calibrator standards and quality control samples are routinely prepared in pooled human plasma, variations in the extraction recovery and/or matrix effect between pooled plasma and individual patient plasma can cause erroneous measurements. Using both pooled human plasma as well as individual healthy donor and cancer patient plasma samples, we evaluated the analytical performance of two classes of internal standards (i.e., non-isotope-labeled and isotope-labeled) in the quantitative LC-MS/MS analysis of lapatinib. After exhaustive extraction with organic solvent, the recovery of lapatinib, a highly plasma protein-bound drug, varied up to 2.4-fold (range, 29-70%) in 6 different donors of plasma and varied up to 3.5-fold (range, 16-56%) in the pretreatment plasma samples from 6 cancer patients. No apparent matrix effects were observed for lapatinib in both pooled and individual donor or patient plasma samples. The calibration curve range was 5-5000ng/ml of lapatinib in plasma. Both the non-isotope-labeled (zileuton) and isotope-labeled (lapatinib-d3) internal standard methods showed acceptable specificity, accuracy (within 100±10%), and precision (<11%) in the determination of lapatinib in pooled human plasma. Nevertheless, only the isotope-labeled internal standard could correct for the interindividual variability in the recovery of lapatinib from patient plasma samples. As inter- and intra-patient matrix variability is commonly presented in the clinical setting, this study provides an example underscoring the importance of using a stable isotope-labeled internal standard in quantitative LC-MS/MS analysis for therapeutic drug monitoring or pharmacokinetic evaluation.
建立和验证 LC-MS/MS 方法通常使用混合人血浆进行,这可能无法解释个体间基质的变化。由于校准标准品和质控样品通常在混合人血浆中制备,因此混合血浆和个体患者血浆之间的提取回收率和/或基质效应的变化可能导致测量错误。我们使用混合人血浆以及个体健康供体和癌症患者血浆样本,评估了两种内标(即非同位素标记和同位素标记)在拉帕替尼定量 LC-MS/MS 分析中的分析性能。在有机溶剂的充分提取后,高度与血浆蛋白结合的拉帕替尼的回收率在 6 位不同供体的血浆中变化高达 2.4 倍(范围为 29-70%),在 6 位癌症患者的预处理血浆样本中变化高达 3.5 倍(范围为 16-56%)。在混合和个体供体或患者血浆样本中,均未观察到拉帕替尼的明显基质效应。拉帕替尼在血浆中的校准曲线范围为 5-5000ng/ml。非同位素标记(齐留通)和同位素标记(拉帕替尼-d3)内标方法在混合人血浆中测定拉帕替尼时均表现出可接受的特异性、准确度(在 100±10%范围内)和精密度(<11%)。然而,只有同位素标记的内标可以纠正从患者血浆样本中回收拉帕替尼的个体间变异性。由于在临床环境中通常存在个体间和个体内基质变异性,因此本研究提供了一个示例,强调了在治疗药物监测或药代动力学评估的定量 LC-MS/MS 分析中使用稳定同位素标记内标重要性。